|
|
Latest Story |
IGC-AD1's Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two |
BusinessWire |
IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) today announced that interim data from its Phase 2 clinical trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer's at week two compared to placebo. |
Full Story → |
Headline News |
IGC Pharma Adds Advisor in Artificial Intelligence |
9:00a ET April 9 '24 BusinessWire |
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research |
9:03a ET April 3 '24 News Direct |
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock |
3:00p ET March 26 '24 BusinessWire |
More News → |
|
April 17 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Previous data from yesterday, April 16 '24. |